Beken Bio: Liquid Biopsy Detection of Ovarian Cancer Targeting Novel Extracellular Vesicle Biomarkers

Prevention and Diagnostic Tools

Christopher Millan, PhD

Every year, too many lives are lost to cancers that could be treated if diagnosed earlier. At Beken, we are dedicated to changing that. We are developing a groundbreaking liquid biopsy—a simple blood test—that detects cancer at its earliest stages by identifying tiny particles called extracellular vesicles (EVs). These particles are released by tumors early in their growth, making them a key target for early detection. By spotting cancer sooner, our goal is to connect patients with life-saving treatment when it matters most.

“Our work focuses on developing a liquid biopsy that enables earlier diagnosis of ovarian cancer by detecting tumor-derived extracellular vesicles (EVs) in the blood. By identifying cancer at an earlier, more treatable stage, we aim to improve survival rates and reduce the burden of late-stage diagnoses. This grant from the Curebound foundation will accelerate clinical testing of our technology and serve as an incredible entry point into San Diego’s network of brilliant cancer researchers and clinicians, fostering future collaborations within local institutes and clinics.” – Christopher Millan, PhD